title: Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase.
abstract: The role of the supplementary interaction between virion-bound host ICAM-1 and LFA-1 on target cells in sensitivity to neutralization of human immunodeficiency virus type 1 (HIV-1) is poorly studied. Serum samples from four long-term nonprogressors (LTNPs) and sequential sera from one progressor were used to assess neutralization sensitivity of isogenic ICAM-1-negative and ICAM-1-bearing HIV-1(NL4-3), a prototype of T-cell-line-adapted viruses. We found that virus neutralization sensitivity to the studied sera is not modified by the additional interaction between virally embedded ICAM-1 and LFA-1 under an inactive state. However, expression on the target cell surface of an activated LFA-1 form renders ICAM-1-bearing virus particles, but not viruses devoid of ICAM-1, more refractory to neutralization by sera from three out of four LTNPs and all sequential sera from the person who has experienced a progression of the HIV-1-associated disease. Although no conclusive correlation could be drawn between virus susceptibility to neutralization and the disease status or stages of HIV-1 infection, these findings demonstrate that other nonspecific virus-cell interactions mediated by virion-anchored host proteins and their normal cognate ligands on target cells represent factors that can affect the mechanism of HIV-1 neutralization.
authors.affiliation: Centre de Recherche en Infectiologie, Hôpital CHUL, Centre Hospitalier Universitaire de Québec, and Département de Biologie médicale, Faculté de Médecine, Université Laval, G1V 4G2, Québec (QC), Canada.
authors.forename: Martine
authors.initials: M
authors.lastname: Losier
authors.forename: Jean François
authors.initials: JF
authors.lastname: Fortin
authors.forename: Réjean
authors.initials: R
authors.lastname: Cantin
authors.forename: Michel G
authors.initials: MG
authors.lastname: Bergeron
authors.forename: Michel J
authors.initials: MJ
authors.lastname: Tremblay
mesh_terms: D018791:CD4 Lymphocyte Count; D002460:Cell Line / Q000821:virology; D018450:Disease Progression; D004306:Dose-Response Relationship, Immunologic; D015483:HIV Antibodies / Q000276:immunology; D015658:HIV Infections / Q000097:blood / Q000276:immunology*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007106:Immune Sera / Q000276:immunology*; D018799:Intercellular Adhesion Molecule-1 / Q000096:biosynthesis / Q000097:blood / Q000276:immunology*; D008156:Luciferases; D016169:Lymphocyte Function-Associated Antigen-1 / Q000097:blood / Q000276:immunology*; D009500:Neutralization Tests / Q000379:methods*; D011485:Protein Binding; D015203:Reproducibility of Results; D019562:Viral Load / Q000379:methods
chemical_list: D015483:HIV Antibodies; D007106:Immune Sera; D016169:Lymphocyte Function-Associated Antigen-1; D018799:Intercellular Adhesion Molecule-1; D008156:Luciferases